Truist raised the firm’s price target on Amrize (AMRZ) to $75 from $60 and keeps a Buy rating on the shares. The company’s Q4 results were as expected, though the stock is rising and now starting to see some multiple improvement given that guidance is for growth in 2026, despite some headwinds, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ:
- Amrize price target raised to $70 from $64 at Oppenheimer
- Amrize price target raised to $66 from $59 at Wells Fargo
- Amrize price target raised to $70 from $64 at Berenberg
- Amrize Expands West Texas Footprint With Acquisition of PB Materials
- Amrize Files 2025 Form 10-K, Highlighting $11.8 Billion in Revenue and North American Scale